中国医学前沿杂志（电子版）2025，Vol.17Issue(4)：24-29,6.DOI:10.12037/YXQY.2025.04-05
德曲妥珠单抗在人表皮生长因子2阳性或低表达乳腺癌中的疗效及安全性分析
Efficacy and safety of trastuzumab deruxtecan in HER2 positive or low expression breast cancer
孙玮 1李晶晶 1薛丹 1樊海波 1马勇 2崔灵芝1
作者信息
- 1. 山西省肿瘤医院 中国医学科学院肿瘤医院山西医院 山西医科大学附属肿瘤医院乳腺内科,山西 太原 030012
- 2. 山西省肿瘤医院 中国医学科学院肿瘤医院山西医院 山西医科大学附属肿瘤医院胸外科,山西 太原 030012
- 折叠
摘要
Abstract
Objective To explore the efficacy and safety of trastuzumab deruxtecan(T-DXd)in HER2 positive or low expression breast cancer.Methods A total of 72 patients with breast cancer exhibiting HER2 positive or low expression who were admitted to our hospital between January 2021 and January 2023 were selected,with 36 patients receiving T-DXd as the observation group and 36 patients receiving Trastuzumab Emtansine(TDM1)s the control group.We recorded demographic data and clinical efficacy outcomes,including objective response rate(ORR)and disease control rate(DCR).Additionally,we assessed the quality of life in both groups before and after treatment using the Breast Cancer Patient Quality of Life Scale(FACT-B).Patients were followed up to document their progression-free survival(PFS).Furthermore,binary logistic regression analysis was employed to identify factors influencing the objective response within the observation group.Results After treatment,there was no statistically significant difference in the overall response rate(ORR)between the two groups(P>0.05).the DCR in the observation group(83.33%)was significantly higher than that in the control group(61.11%,P<0.05).The disease control rate(DCR)of the observation group was 83.33%,which was significantly higher than the 61.11%observed in the control group(P<0.05).Additionally,there were no statistically significant differences in ORR and DCR between HER2 positive patients and those with low HER2 expression within the observation group(P>0.05).Binary logistic regression analysis indicated that visceral crisis and having more than four lines of prior treatment were risk factors associated with failure to achieve objective remission during T-DXd treatment for breast cancer.Furthermore,patients in both groups exhibited an increase in FACT-B scores post-treatment,with a greater improvement in the observational group(P<0.05).Patients in both groups experienced varying degrees of adverse reactions,with decreased appetite and nausea being reported as the most common side effects.The median PFS in the observation group was better than that in the T-DM1 group(19.5 months vs.8.5 months,P<0.05).The multifactorial Cox proportional hazards regression model indicated that visceral crisis,line of therapy,and T-DXd were related factors affecting PFS.Conclusions The therapeutic effect of T-DXd on HER-2 positive or low expression breast cancer is better than that of T-DM1.T-DXd has a positive impact on the quality of life of patients,which can extend their survival period,but there are also some adverse reactions.The monitoring of adverse reactions during treatment should be strengthened.关键词
德曲妥珠单抗/人表皮生长因子受体2/乳腺癌/生活质量/不良反应Key words
Trastuzumab deruxtecan/HER-2/Breast cancer/Quality of life/Adverse reactions引用本文复制引用
孙玮,李晶晶,薛丹,樊海波,马勇,崔灵芝..德曲妥珠单抗在人表皮生长因子2阳性或低表达乳腺癌中的疗效及安全性分析[J].中国医学前沿杂志（电子版）,2025,17(4):24-29,6.
